Delivery Order SPE2DB24D2205-SPE2DB25FEHKR
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $8,009.57 to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Gemtesa 75 mg tablets (90-unit quantity). This is a firm fixed-price, non-set-aside contract with a completion date of August 18, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, was competitively selected...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count) under a firm fixed price contract valued at $3,328.73. The award, issued on August 18, 2025, with an ultimate completion date of August 19, 2025, represents a competitive, non-set-aside procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance and is a major pharmaceutical distributor providing critical medical supplies to...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,095.26 to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Gemtesa 75 mg tablets (90-count units). This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 10, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $75,373.59 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count units). This firm fixed-price contract, awarded on August 11, 2025, represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The contract contains no set-aside...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) with a ceiling value of $52,500.45. This is a firm fixed price delivery order with an ultimate completion date of July 28, 2025, and represents a non-competitive set-aside award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order is issued...
- The Defense Logistics Agency awarded a $8,938.51 delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Gemtesa 75 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation, with an ultimate completion date of September 12, 2025. The award will be performed in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order represents a child contract under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,479.31 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (30-count), with an ultimate completion date of September 4, 2025. The contract, awarded on September 3, 2025, utilizes firm fixed-price pricing under a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, performed the work at its corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) valued at $19,403.29. This firm fixed-price delivery order, with an ultimate completion date of August 15, 2025, represents a non-competitive set-aside award and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $7,772.26 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Gemtesa 75 mg tablets (30-count units). The contract represents a firm fixed price, non-set-aside award with an ultimate completion date of September 4, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $7,437.20 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count) on August 28, 2025, with completion targeted for August 29, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award to the pharmaceutical distributor's Corporate Office, with performance occurring at the company's headquarters in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen's existing Indefinite...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEHKRDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) valued at $85,855.62. This firm fixed-price delivery order, which is not set-aside and was competitively awarded, represents performance through September 12, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. The award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vehicle through December 2026 that provides comprehensive pharmaceutical and medical supply support to military healthcare programs globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical federal medical vendor specializing in brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. The company's extensive contract portfolio with the Defense Logistics Agency and Defense Health Agency demonstrates its established capability to meet federal procurement requirements through competitive selection. Gemtesa (mirabegron), a beta-3 agonist used in the treatment of overactive bladder, represents one element of the company's broader pharmaceutical supply mission supporting military and veteran healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $85.9k | 9/11/25 |